1110641-70-7

Basic information

• Product Name: (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one
• Synonyms: (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one
• CAS NO: 1110641-70-7
• Molecular Weight: 432.357
• Mol File: 1110641-70-7.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one(1110641-70-7)
• EPA Substance Registry System: (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one(1110641-70-7)

Safety Data

• Hazardous Substances Data: 1110641-70-7(Hazardous Substances Data)

Upstream product

• 1110642-44-8 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propanal 
• 1383540-79-1 (S)-2-bromo-N-(1-(4-bromophenyl)ethyl)acetamide 
• 1383540-75-7 (R)-3-hydroxy-5-methyl-3-phenyl-5-(trimethylsilyloxy)hexanal 
• 1383540-73-5 phenyl (S)-1-(4-bromophenyl)ethyl((S)-3,5-dihydroxy-5-methyl-3-phenylhexyl)carbamate 
• 1383540-71-3 (R)-N-((S)-1-(4-bromophenyl)ethyl)-3,5-dihydroxy-5-methyl-3-phenylhexanamide 
• 144741-40-2 3-methyl-1-phenyl-3-(trimethylsilyloxy)butan-1-one 
• 43108-74-3 3-hydroxy-3-methyl-1-phenyl-1-butanone 
• 98-86-2 acetophenone 
• 143427-44-5 1-chloro-3-phenylhex-5-en-3-ol 
• 1110641-67-2 (R)-3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-(2-methyl-allyl)-6-phenyl-perhydro-1,3-oxazin-2-one 
• 149552-52-3 (+)-(1S)-1-(4-bromophenyl)ethyl isocyanate 
• 936-59-4 3-chloropropiophenone 
• 27298-97-1 (S)-1-(4-bromophenyl)ethylamine 
• 1110641-69-4 (S)-3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-(2-methyl-oxiranylmethyl)-6-phenyl-perhydro-1,3-oxazin-2-one 

Downstream Products

• 1110642-47-1 (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-an-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one 
• 1237534-48-3 4-{(S)-1-[(S)-6-(2-hydroxy-2-methyl-propyl)-2-oxo-6-phenyl-[1,3]oxazinan-3-yl]-ethyl}-benzonitrile 
• 1193334-13-2 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one 
• 1259034-36-0 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(3-hydroxy-3-methylbut-ynyl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one 
• 1259034-71-3 (S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-3-[(S)-1-(4-trimethylsilylethynyl-phenyl)-ethyl]-[1,3]oxazinan-2-one 
• 1259034-67-7 (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-((triethylsilyl)ethynyl)phenyl)ethyl)-1,3-oxazinan-2-one 
• 1259034-68-8 (S)-3-((S)-1-(4-ethynylphenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one 
• 1259034-66-6 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-((2-methoxypyridin-4-yl)ethynyl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one 
• 1259034-70-2 (S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-ylethynyl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one 
• 1259034-39-3 4-(4-((S)-1-((S)-6-(2-hydroxy-2-methylpropyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)ethyl)phenyl)-2,2-dimethylbut-3-ynoic acid 
• 1259034-41-7 4-(4-((S)-1-((S)-6-(2-hydroxy-2-methylpropyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)ethyl)phenyl)-N,N,2,2-tetramethylbut-3-ynamide 
• 1259034-42-8 (S)-3-((S)-1-(4-(4-(azetidin-1-yl)-3,3-dimethyl-4-oxobut-1-ynyl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one 
• 1259034-40-6 butyl 4-(4-((S)-1-((S)-6-(2-hydroxy-2-methylpropyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)ethyl)phenyl)-2,2-dimethylbut-3-ynoate 
• 1114573-33-9 4-(4-{(S)-1-[(S)-6-(2-hydroxy-2-methylpropyl)-2-oxo-6-phenyl-[1,3]oxazinan-3-yl]ethyl}phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor

A potent, in vivo efficacious 11β hydroxysteroid dehydrogenase type 1 (11β HSD1) inhibitor (11j) has been identified. Compound 11j inhibited 11β HSD1 activity in human adipocytes with an IC50 of 4.3?nM and in primary human adipose tissue with an IC80 of 53?nM. Oral administration of 11j to cynomolgus monkey inhibited 11β HSD1 activity in adipose tissue. Compound 11j exhibited >1000× selectivity over other hydroxysteroid dehydrogenases, displays desirable pharmacodynamic properties and entered human clinical trials in 2011.

INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1

This invention relates to novel compounds of the Formula (I), (Ia1-10), (Ib1-10), (Ic1-10), (Id1-7), (Ie1-5) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1

This invention relates to novel compounds of the Formula Formulas (I), (Ia1-20), (Ib1-20), (Ic1-20), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.